In this video from Mass General Hospital from May 2016, it was announced that Phase II funding had been received for a multi-institution project to study patients who have survived ovarian cancer for 10 or more years. Published on May 6, 2016.
In this video, Dr. Michael Birrer talks about targeting either VEGF or ANG2 in gynecologic cancers. VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels. Published on Nov 25, 2015.
In this video from Onc Live TV, Dr. Birrer discusses how progression-free survival and overall survival are holding back the approval of drugs for ovarian cancer patients. Published on Oct 16, 2013.
In this lecture from January 2013 by Dr. Michael Birrer, prospects for targeted therapy in ovarian cancer are discussed. Published on Jan 21, 2013.